ArticleBMC cancer2018
Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Calcium and Cadmium Activate ESRRB to Mediate Cell Stemness and Pluripotency.International journal of molecular sciences · 2025Article
- Metabolomic Analysis of Breast Cancer in Colombian Patients: Exploring Molecular Signatures in Different Subtypes and Stages.International journal of molecular sciences · 2025Article
- CircRNAs: a novel potential strategy to treat breast cancer.Frontiers in immunology · 2025Review
- Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease.Breast cancer research and treatment · 2024Review
- Receptor discordance after nipple-sparing mastectomy.Surgery in practice and science · 2024Article
- Article
- Article
- Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases.Cancers · 2023Article
- Natural-Product-Derived Adjunctive Treatments to Conventional Therapy and Their Immunoregulatory Activities in Triple-Negative Breast Cancer.Molecules (Basel, Switzerland) · 2023Review
- Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications.EJNMMI research · 2023Review
- Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors.Frontiers in oncology · 2023Article
- The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry.Breast cancer research and treatment · 2022Article
- Mex-3 RNA binding MEX3A promotes the proliferation and migration of breast cancer cells via regulating RhoA/ROCK1/LIMK1 signaling pathway.Bioengineered · 2021Article
- Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients.NPJ breast cancer · 2021Article
- Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients.Frontiers in oncology · 2021Article
- A 23-gene prognostic classifier for prediction of recurrence and survival for Asian breast cancer patients.Bioscience reports · 2020Article
- Receptor Discordance of Metastatic Breast Cancer Depending on the Molecular Subtype.Breast care (Basel, Switzerland) · 2020Article
- Circular RNA hsa_circ_0001785 inhibits the proliferation, migration and invasion of breast cancer cells in vitro and in vivo by sponging miR-942 to upregulate SOCS3.Cell cycle (Georgetown, Tex.) · 2020Article
- Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival.Neuro-oncology · 2020Article
- circ_103809 promotes breast cancer progression by regulating the PI3K/AKT signaling pathway.Oncology letters · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent studies have shown that breast cancer subtype can change from the primary tumour to the recurrence. Discordance between primary and recurrent breast cancer has implications for further treatment and ultimately prognosis. The aim of the study was to determine the rate of change between primary and recurrence of breast cancer and to assess the impact of these changes on survival and potential treatment options.
methodsPatient demographics were collected on those who underwent surgery for breast cancer between 2001 and 2014 and had a recurrence with biopsy results and pathology scoring of both the primary and recurrence.
resultsOne hundred thirty two consecutive patients were included. There were 31 (23.5%) changes in subtype. Discordance occurred most frequently in luminal A breast cancer (n = 20), followed by triple negative (n = 4), luminal B (n = 3) and HER2 (n = 3). Patients who changed from luminal A to triple negative (n = 18) had a significantly worse post-recurrence survival (p < 0.05) with overall survival approaching significance (p = 0.064) compared to concordant luminal A cases (n = 46). Overall receptor discordance rates were: estrogen receptor 20.4% (n = 27), progesterone receptor 37.7% (n = 50) and HER2 3% (n = 4). Loss of estrogen receptor and progesterone receptor was more common than gain (21 vs. 6 (p = 0.04) and 44 vs. 6 (p = 0.01) respectively). Nine patients (6.8%) gained receptor status potentially impacting treatment options.
conclusionDiscordance in subtype and receptor status occurs between primary and recurrent breast cancer, ultimately affecting survival and potentially impacting treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.